dihydroxyphenylalanine has been researched along with Depression in 114 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Until recently, all drugs used to treat depression appeared to enhance neurotransmission in one or both of these systems, which was used to explain their antidepressant actions (Gelenberg and Klerman, 1978)." | 7.75 | Tyrosine for the treatment of depression. ( Gelenberg, AJ; Gibson, CJ, 1984) |
| "The administration of catechol-O-methyltransferase inhibitors alone changed neither the behavior of the rats in two animal models of depression, the forced swimming test (entacapone and tolcapone) or in the learned helplessness paradigm (tolcapone), nor the locomotor activity." | 7.69 | Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression. ( Lang, A; Männistö, PT; Rauhala, P; Vasar, E, 1995) |
| "Until recently, all drugs used to treat depression appeared to enhance neurotransmission in one or both of these systems, which was used to explain their antidepressant actions (Gelenberg and Klerman, 1978)." | 3.75 | Tyrosine for the treatment of depression. ( Gelenberg, AJ; Gibson, CJ, 1984) |
| "The administration of catechol-O-methyltransferase inhibitors alone changed neither the behavior of the rats in two animal models of depression, the forced swimming test (entacapone and tolcapone) or in the learned helplessness paradigm (tolcapone), nor the locomotor activity." | 3.69 | Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression. ( Lang, A; Männistö, PT; Rauhala, P; Vasar, E, 1995) |
| "The probenecid technique was used in study of the central dopamine DA metabolism in patients with depressions, psychotic disorders, and Parkinson's disease." | 3.65 | Dopamine metabolism in depressions, psychoses, and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders. ( Korf, J; Praag, HM; Schut, T, 1975) |
| "Patients with Parkinson's disease have a decrement in homovanillic acid that is reversed by treatment with L-3,4-dihydroxyphenylalanine." | 1.27 | Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method. ( Aguado, EG; de Yebenes, JG; Mena, MA, 1984) |
| "25% of patients with Parkinson's disease demonstrate the first symptoms with 70 years." | 1.26 | [Senile Parkinsonism: its motor and psychological defects]. ( Birkmayer, W, 1982) |
| "Fatigue, confusion, and depression were measured on the Profile of Mood States, while barometric pressure and the ANS indices of heart rate and body temperature were also recorded." | 1.26 | Alertness and clear thinking as characteristics of high naturally occurring autonomic nervous system arousal. ( Schubert, DS, 1977) |
| "Psychogenic depression is characterized by a domination of desynchronized activity of low volts in the EEG and the existence of expressed sympathicotony of the peripheral vegetative system, while statistically significant shifts of the vascular tonus and catecholamine excreation are absent." | 1.26 | [Pathophysiologic mechanisms of depressive states of endogenous or exogenous origin]. ( Biriukovich, PV; Sinitskiĭ, VN; Usherenko, LS, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 111 (97.37) | 18.7374 |
| 1990's | 2 (1.75) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (0.88) | 2.80 |
| Authors | Studies |
|---|---|
| Béreau, M | 1 |
| Van Waes, V | 1 |
| Servant, M | 1 |
| Magnin, E | 1 |
| Tatu, L | 1 |
| Anheim, M | 1 |
| KLERMAN, GL | 1 |
| SCHILDKRAUT, JJ | 2 |
| HASENBUSH, LL | 1 |
| GREENBLATT, M | 1 |
| FRIEND, DG | 1 |
| SAINTJEAN, A | 1 |
| DONALD, MW | 1 |
| BAN, TA | 1 |
| TURNER, WJ | 1 |
| MERLIS, S | 2 |
| Casacchia, M | 1 |
| Ianiri, G | 1 |
| Birkmayer, W | 2 |
| Misionzhnik, EIu | 1 |
| Vertogradova, OP | 1 |
| Krasnov, VN | 1 |
| Salenko, BB | 1 |
| Mena, MA | 1 |
| Aguado, EG | 1 |
| de Yebenes, JG | 1 |
| Gelenberg, AJ | 1 |
| Gibson, CJ | 1 |
| Männistö, PT | 1 |
| Lang, A | 1 |
| Rauhala, P | 1 |
| Vasar, E | 1 |
| Schubert, DS | 1 |
| Zarifian, E | 1 |
| Mato, M | 1 |
| Uchiyama, Y | 1 |
| Kurihara, K | 1 |
| Karasawa, T | 1 |
| Biriukovich, PV | 1 |
| Sinitskiĭ, VN | 1 |
| Usherenko, LS | 1 |
| Sachar, EJ | 3 |
| Altman, N | 2 |
| Gruen, PH | 1 |
| Glassman, A | 1 |
| Halpern, FS | 1 |
| Sassin, J | 3 |
| Praag, HM | 1 |
| Korf, J | 1 |
| Schut, T | 1 |
| Nygaard, TG | 1 |
| Marsden, CD | 1 |
| Fahn, S | 2 |
| Eisenhofer, G | 1 |
| Goldstein, DS | 1 |
| Stull, R | 1 |
| Keiser, HR | 1 |
| Sunderland, T | 1 |
| Murphy, DL | 11 |
| Kopin, IJ | 1 |
| Lehmann, J | 1 |
| Coppen, A | 1 |
| Metcalfe, M | 1 |
| Carroll, JD | 1 |
| Morris, JG | 1 |
| Riklan, M | 4 |
| Halgin, R | 1 |
| Maskin, M | 1 |
| Weissman, D | 1 |
| Maskin, MB | 2 |
| Chabot, D | 2 |
| Marsh, GG | 1 |
| Markham, CH | 1 |
| Horn, S | 1 |
| Goodwin, FK | 14 |
| Bunney, WE | 8 |
| Persson, T | 2 |
| Roos, BE | 2 |
| Janowsky, DS | 1 |
| Davis, JM | 1 |
| Brodie, HK | 6 |
| Chase, TN | 1 |
| Wagshul, AM | 1 |
| Daroff, RB | 1 |
| Angus, S | 1 |
| Jenkins, RB | 2 |
| Groh, RH | 2 |
| Abrams, R | 1 |
| Damásio, AR | 2 |
| Antunes, JL | 1 |
| Macedo, C | 2 |
| Matussek, N | 6 |
| Benkert, O | 2 |
| Schneider, K | 2 |
| Otten, H | 2 |
| Pohlmeier, H | 4 |
| Fujiwara, J | 1 |
| Otsuki, S | 1 |
| Gordon, EK | 1 |
| Oliver, J | 1 |
| Van Woert, MH | 1 |
| Ambani, LM | 1 |
| Levine, RJ | 1 |
| Post, RM | 1 |
| Paul, MI | 1 |
| Cramer, H | 1 |
| McClure, DJ | 1 |
| Pare, CM | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Frantz, AG | 1 |
| Ambrozi, L | 1 |
| Danielczyk, W | 1 |
| Neumayer, E | 1 |
| Riederer, P | 1 |
| Mandell, AJ | 1 |
| Spooner, CE | 1 |
| Beardsley, JV | 1 |
| Puletti, F | 1 |
| Angrist, B | 1 |
| Sathananthan, G | 1 |
| Wilk, S | 1 |
| Gershon, S | 2 |
| Kicey, CA | 1 |
| Sano, I | 1 |
| Taniguchi, K | 1 |
| Wälzholz, U | 1 |
| Náhunek, K | 1 |
| Svestka, J | 1 |
| Kamenická, V | 1 |
| Rodová, A | 1 |
| Yaryura-Tobias, JA | 1 |
| Diamond, B | 1 |
| Fischer, PA | 2 |
| Schneider, E | 1 |
| Jacobi, P | 1 |
| Maxion, H | 1 |
| Stancer, HC | 1 |
| Whybrow, P | 1 |
| Parlatore, A | 1 |
| Sack, RL | 1 |
| Plotnikoff, NP | 1 |
| Kastin, AJ | 1 |
| Anderson, MS | 1 |
| Schally, AV | 1 |
| Mushrush, G | 1 |
| Perlow, M | 1 |
| Weitzman, ED | 1 |
| Celesia, GG | 2 |
| Wanamaker, WM | 1 |
| Schwab, RS | 1 |
| Poskanzer, DC | 1 |
| England, AC | 1 |
| Young, RR | 1 |
| Reveno, WS | 2 |
| Bauer, RB | 2 |
| Rosenbaum, H | 2 |
| Tissot, R | 3 |
| de Ajuriaguerra, J | 2 |
| Müller-Plettenberg, D | 1 |
| Henry, GM | 1 |
| Weingartner, H | 1 |
| Bartholini, G | 1 |
| Constantinidis, J | 1 |
| Eisenring, JJ | 2 |
| Geissbühler, F | 1 |
| Yanniotis, G | 2 |
| Dick, P | 1 |
| Paulson, GW | 1 |
| Brown, WA | 1 |
| Almici, GM | 1 |
| Sbarbaro, V | 1 |
| Gehlen, W | 1 |
| Gauthier, G | 1 |
| Juge, O | 1 |
| Birchler, A | 1 |
| Granerus, AK | 1 |
| Magnusson, T | 1 |
| Svanborg, A | 1 |
| Sutcliffe, RL | 1 |
| Moir, AT | 1 |
| Ashcroft, GW | 1 |
| Crawford, TB | 1 |
| Eccleston, D | 1 |
| Guldberg, HC | 1 |
| Rysánek, K | 1 |
| Guglielmi, L | 1 |
| Vecchi, L | 1 |
| Schön, I | 1 |
| Lipman, IJ | 1 |
| Selby, G | 1 |
| Raft, D | 1 |
| Newman, M | 1 |
| Spencer, R | 1 |
| Gershon, ES | 2 |
| Sanghvi, I | 1 |
| Urquiaga, X | 1 |
| Barbieri, NF | 1 |
| Megna, GF | 1 |
| Micalizzi, V | 1 |
| Pigneri, MT | 1 |
| Puca, FM | 1 |
| Lobo-Antunes, J | 1 |
| Dunner, DL | 1 |
| Martin, WE | 1 |
| Dewhurst, WG | 1 |
| Barr, AN | 1 |
| Schwieger, AC | 1 |
| Jenkins, AC | 1 |
| Krasner, N | 1 |
| Cornelius, JM | 1 |
| O'Brien, CP | 1 |
| DiGiacomo, JN | 1 |
| Schwarz, GA | 1 |
| Wålinder, J | 1 |
| Ingvarsson, CG | 1 |
| Rüther, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Reference Values for Plasma Catechols[NCT00267904] | Phase 1 | 46 participants (Actual) | Interventional | 2006-03-08 | Completed | ||
| Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)[NCT02202551] | Phase 3 | 223 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.~Part I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).~Total range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.~Parts I, II, and III are summed to make the total score." (NCT02202551)
Timeframe: Up to 101 weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change from Baseline at Week 8 | Change from Baseline at Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| ADS-5102 1A | 41.8 | 1.2 | 1.6 | 4.8 | 7.5 | 13.2 | 8.8 | 11.7 | 11.3 | 11.4 |
| ADS-5102 Group 1P | 45.6 | -2.8 | -1.4 | 1.5 | -0.4 | 2.6 | 2.6 | 7.3 | 3.7 | 3.7 |
| ADS-5102 Group 2 | 52.8 | 0.8 | 5.7 | 6.5 | 1.6 | 6.1 | 6.1 | 9.4 | 6.4 | 6.5 |
| ADS-5102 Group 3 | 52.4 | -5.3 | -5.2 | -5.3 | -4.8 | -4.6 | -4.6 | -4.9 | 0.9 | 4.1 |
"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.~Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24" (NCT02202551)
Timeframe: 100 Weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change in Baseline from Week 8 | Change in Baseline from Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| Group 1a | 6.5 | -0.2 | -0.8 | -0.3 | 0.0 | 0.2 | 0.4 | 0.9 | 0.4 | 0.4 |
| Group 1P | 9.6 | -3.4 | -3.2 | -3.3 | -2.8 | -2.9 | -3.3 | -2.9 | -2.8 | -2.4 |
| Group 2 | 9.8 | -3.6 | -1.1 | -1.4 | -2.9 | -2.5 | -1.9 | -2.7 | -3.7 | -3.6 |
| Group 3 | 10.4 | -4.0 | -3.9 | -4.4 | -4.7 | -3.6 | -2.5 | -3.7 | -4.3 | -3.6 |
The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). (NCT02202551)
Timeframe: Up to 101 weeks
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AE | Study drug-related AE | SAEs | Permanent discontinuation due to AE | Permanent discontinuation due to drug-related AE | Mild AEs | Moderate AEs | Mild drug-related AE | Moderate drug-related AE | Severe drug-related AE | |
| Group 1a | 57 | 31 | 16 | 12 | 4 | 12 | 25 | 16 | 12 | 3 |
| Group 1P | 70 | 45 | 21 | 21 | 15 | 13 | 36 | 15 | 23 | 7 |
| Group 2 | 23 | 16 | 6 | 6 | 4 | 3 | 13 | 3 | 12 | 1 |
| Group 3 | 55 | 32 | 17 | 10 | 8 | 11 | 26 | 5 | 22 | 5 |
20 reviews available for dihydroxyphenylalanine and Depression
| Article | Year |
|---|---|
Apathy in Parkinson's Disease: Clinical Patterns and Neurobiological Basis.
Topics: Apathy; Depression; Dihydroxyphenylalanine; Humans; Limbic System; Parkinson Disease; Syndrome | 2023 |
Tyrosine for the treatment of depression.
Topics: 5-Hydroxytryptophan; Adult; Animals; Clinical Trials as Topic; Depression; Dihydroxyphenylalanine; D | 1984 |
Biochemistry of depression.
Topics: Brain; Catecholamines; Depression; Dihydroxyphenylalanine; Humans; Intellectual Disability; Serotoni | 1971 |
Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.
Topics: Amantadine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Ganglia Diseases; Brain Che | 1971 |
[Biochemical aspects of human behavior].
Topics: Amantadine; Behavior; Biogenic Amines; Brain; Depression; Dihydroxyphenylalanine; Dopamine; Epinephr | 1973 |
Psychochemical research studies in man.
Topics: Animals; Behavior; Bipolar Disorder; Brain; Brain Chemistry; Depression; Dihydroxyphenylalanine; Hal | 1968 |
[Biochemistry of depression].
Topics: Animals; Bipolar Disorder; Brain; Central Nervous System; Depression; Dihydroxyphenylalanine; Glycol | 1972 |
Psychopharmacology. Yesterday, today and tomorrow: a point of view.
Topics: Affective Symptoms; Amitriptyline; Antidepressive Agents; Canada; Carbonates; Depression; Dihydroxyp | 1973 |
The current status of biological criteria for classifying the depressive disorders and predicting responses to treatment.
Topics: Adult; Aged; Catechol O-Methyltransferase; Depression; Dextroamphetamine; Dihydroxyphenylalanine; Do | 1974 |
Melancholia, a model in madness: a discussion of recent psychobiologic research into depressive illness.
Topics: Adaptation, Psychological; Biogenic Amines; Brain; Depression; Dihydroxyphenylalanine; Emotions; Env | 1973 |
Central dopamine function in affective illness: evidence from precursors, enzyme inhibitors, and studies of central dopamine turnover.
Topics: Adult; Affective Symptoms; Anger; Bipolar Disorder; Central Nervous System; Depression; Diagnosis, D | 1974 |
[Therapy of Parkinsonian syndrome using L-dopa. Current state and problems].
Topics: Administration, Oral; Basal Ganglia Diseases; Carboxy-Lyases; Depression; Dihydroxyphenylalanine; Dr | 1974 |
L-dopa, behavioral activation and psychopathology.
Topics: Anger; Animals; Arousal; Behavior; Behavior, Animal; Bipolar Disorder; Brain; Catecholamines; Cerebr | 1972 |
Use of drugs in the treatment of parkinsonism.
Topics: Amantadine; Depression; Dihydroxyphenylalanine; Feeding and Eating Disorders; Humans; Hypertension; | 1970 |
Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain.
Topics: Amines; Animals; Basal Ganglia; Biological Transport, Active; Blood-Brain Barrier; Brain; Cerebral V | 1970 |
[Relation of monoamines to mental disorders].
Topics: Amines; Animals; Bipolar Disorder; Catecholamines; Central Nervous System; Depression; Dihydroxyphen | 1970 |
[Treatment of Parkinson's disease with L-dopa].
Topics: Arrhythmias, Cardiac; Basal Ganglia; Blood-Brain Barrier; Brain; Depression; Dihydroxyphenylalanine; | 1970 |
L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients.
Topics: Aged; Aggression; Anger; Behavior; Bipolar Disorder; Brain; Brain Chemistry; Carboxy-Lyases; Catecho | 1970 |
L-dopa therapy in Parkinson's disease.
Topics: Delirium; Depression; Dihydroxyphenylalanine; Gastrointestinal Hemorrhage; Hallucinations; Humans; H | 1971 |
Psychiatric side effects of levodopa in man.
Topics: Animals; Brain; Catecholamines; Cognition Disorders; Delirium; Depression; Dihydroxyphenylalanine; D | 1971 |
19 trials available for dihydroxyphenylalanine and Depression
| Article | Year |
|---|---|
Tyrosine for the treatment of depression.
Topics: 5-Hydroxytryptophan; Adult; Animals; Clinical Trials as Topic; Depression; Dihydroxyphenylalanine; D | 1984 |
Levodopa and L-tryptophan therapy in Parkinsonism.
Topics: Aged; Depression; Dihydroxyphenylalanine; Female; Gait; Homovanillic Acid; Humans; Hydroxyindoleacet | 1972 |
Effect of L-DOPA on depression.
Topics: Clinical Trials as Topic; Depression; Dihydroxyphenylalanine; Female; Humans; Middle Aged; Placebos | 1969 |
Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients.
Topics: Adult; Aged; Carboxy-Lyases; Catechols; Chemical Phenomena; Chemistry; Depression; Dihydroxyphenylal | 1970 |
L-dopa with MK 485 for depression.
Topics: Carboxy-Lyases; Clinical Trials as Topic; Depression; Dihydroxyphenylalanine; Humans; Hydrazines; Pl | 1970 |
L-dopa plus decarboxylase inhibitor in depression.
Topics: Carboxy-Lyases; Clinical Trials as Topic; Depression; Dihydroxyphenylalanine; Humans; Hydrazines; Ph | 1970 |
Clinical effects of para-chlorophenylalanine in Parkinson's disease.
Topics: Aged; Benztropine; Brain; Clinical Trials as Topic; Depression; Dihydroxyphenylalanine; Evaluation S | 1972 |
Estimation of brain amine metabolism in affective illness: cerebrospinal fluid studies utilizing probenecid.
Topics: Bipolar Disorder; Brain; Depression; Dihydroxyphenylalanine; Fenclonine; Homovanillic Acid; Humans; | 1974 |
[Management of Parkinson's syndrome using levadopa. Results of a long-term study].
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Clinical Trials as Topic; Depression; Dihyd | 1972 |
Preliminary clinical experience with L-dopa in endogenous depressions.
Topics: Clinical Trials as Topic; Depression; Dihydroxyphenylalanine; Evaluation Studies as Topic; Female; H | 1972 |
Psychiatric manifestations of levodopa.
Topics: Adult; Affect; Clinical Trials as Topic; Depression; Dihydroxyphenylalanine; Evaluation Studies as T | 1972 |
L-dopa, dopamine, and hypomania.
Topics: Adult; Bipolar Disorder; Brain; Brain Chemistry; Depression; Dihydroxyphenylalanine; Dopamine; Dose- | 1973 |
[Effect of a decarboxylase inhibitor (Ro 4-4602) and L-dopa on inhibited depressions. II. Experimental psychological studies].
Topics: Carboxy-Lyases; Clinical Trials as Topic; Depression; Dihydroxyphenylalanine; Humans; Hydrazines; Pl | 1970 |
[Effect of a decarboxylase inhibitor (Ro 4-4602) in combination with L-dopa on inhibited depressions].
Topics: Adolescent; Adult; Aged; Blood Pressure; Carboxy-Lyases; Clinical Trials as Topic; Depression; Dihyd | 1970 |
L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients.
Topics: Aged; Aggression; Anger; Behavior; Bipolar Disorder; Brain; Brain Chemistry; Carboxy-Lyases; Catecho | 1970 |
A preliminary report of Australian trials with L-dopa.
Topics: Activities of Daily Living; Adult; Aged; Australia; Brain; Clinical Trials as Topic; Depression; Dih | 1971 |
Clinical and animal experiments concerning the function of brain catecholamines.
Topics: Animals; Antidepressive Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Ca | 1971 |
The effect of L-DOPA treatment on brain serotonin metabolism in depressed patients.
Topics: Brain; Depression; Dihydroxyphenylalanine; Humans; Hydroxyindoleacetic Acid; Phenylacetates; Placebo | 1971 |
[The effects of dopa on inhibited depressions].
Topics: Blood Pressure Determination; Depression; Dihydroxyphenylalanine; Drug Synergism; Humans; Placebos; | 1966 |
77 other studies available for dihydroxyphenylalanine and Depression
| Article | Year |
|---|---|
CLINICAL EXPERIENCE WITH DIHYDROXYPHENYLALANINE (DOPA) IN DEPRESSION.
Topics: Depression; Depressive Disorder; Dihydroxyphenylalanine; Humans; Monoamine Oxidase Inhibitors; Place | 1963 |
[THE PSYCHOPHYSIOLOGICAL EFFECTS OF METHYLDOPA].
Topics: Blood Pressure; Blood Pressure Determination; Depression; Depressive Disorder; Dihydroxyphenylalanin | 1963 |
A CLINICAL TRIAL OF PARGYLINE AND DOPA IN PSYCHOTIC SUBJECTS.
Topics: Adolescent; Biomedical Research; Brain; Brain Damage, Chronic; Depression; Depressive Disorder, Majo | 1964 |
[Drug-induced depression].
Topics: Adrenal Cortex Hormones; Antipsychotic Agents; Contraceptives, Oral; Depression; Dihydroxyphenylalan | 1980 |
[Senile Parkinsonism: its motor and psychological defects].
Topics: Aged; Antidepressive Agents; Depression; Dihydroxyphenylalanine; Humans; Motor Activity; Neurotransm | 1982 |
[Changes in the levels of adrenergic and serotoninergic indices in patients with depressive states].
Topics: Adolescent; Adult; Biogenic Amines; Depression; Dihydroxyphenylalanine; Dopamine; Epinephrine; Homov | 1981 |
Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Chromatography, High Pressure Liquid; Depression; | 1984 |
Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression.
Topics: Analysis of Variance; Animals; Avoidance Learning; Behavior, Animal; Benzophenones; Carbidopa; Catec | 1995 |
Alertness and clear thinking as characteristics of high naturally occurring autonomic nervous system arousal.
Topics: Adult; Aged; Aggression; Anxiety; Arousal; Atmospheric Pressure; Autonomic Nervous System; Body Temp | 1977 |
[Dopa and dopamine agonists in depression (author's transl)].
Topics: Animals; Brain; Depression; Dihydroxyphenylalanine; Dopamine; Humans; Levodopa; Receptors, Dopamine; | 1979 |
Fluorescent substance in leukocytes and platelets of psychiatric patients.
Topics: Bipolar Disorder; Blood Platelets; Depression; Dihydroxyphenylalanine; Dopamine; Histocytochemistry; | 1977 |
[Pathophysiologic mechanisms of depressive states of endogenous or exogenous origin].
Topics: Adult; Autonomic Nervous System; Biogenic Amines; Brain; Cerebral Cortex; Chlorpromazine; Depression | 1978 |
Human growth hormone response to levodopa. Relation to menopause, depression, and plasma dopa concentration.
Topics: Adult; Age Factors; Aged; Depression; Dihydroxyphenylalanine; Female; Growth Hormone; Humans; Levodo | 1975 |
Dopamine metabolism in depressions, psychoses, and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders.
Topics: Adjustment Disorders; Bipolar Disorder; Brain; Carboxy-Lyases; Depression; Dihydroxyphenylalanine; D | 1975 |
Dopa-responsive dystonia: long-term treatment response and prognosis.
Topics: Adolescent; Adult; Carbamazepine; Child; Child, Preschool; Depression; Dihydroxyphenylalanine; Disab | 1991 |
Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase.
Topics: Alzheimer Disease; Animals; Catecholamines; Chromatography, Liquid; Depression; Dihydroxyphenylalani | 1986 |
Levodopa and depression in parkinsonism.
Topics: Depression; Dihydroxyphenylalanine; Drug Synergism; Humans; Parkinson Disease; Tryptophan | 1971 |
Psychological studies of longer range L-DOPA therapy in Parkinsonism.
Topics: Age Factors; Arousal; Bender-Gestalt Test; Cognition; Depression; Dihydroxyphenylalanine; Educationa | 1973 |
Emotional functions in short-term vs. long-term L-Dopa therapy in Parkinsonism.
Topics: Depression; Dihydroxyphenylalanine; Emotions; Female; Humans; Male; Middle Aged; MMPI; Parkinson Dis | 1973 |
Does levodopa alter depression and psychopathology in Parkinsonism patients?
Topics: Adult; Aged; Depression; Dihydroxyphenylalanine; Emotions; Evaluation Studies as Topic; Female; Huma | 1973 |
Some psychological factors in Parkinsonism.
Topics: Age Factors; Analysis of Variance; Cognition Disorders; Depression; Dihydroxyphenylalanine; Disabili | 1974 |
Clinical and pharmacological investigations of the psychobiology of the affective disorders.
Topics: Antidepressive Agents; Behavior; Bipolar Disorder; Catecholamines; Depression; Dihydroxyphenylalanin | 1971 |
5-hydroxytryptophan for depression.
Topics: 5-Hydroxytryptophan; Amitriptyline; Depression; Dihydroxyphenylalanine; Electroconvulsive Therapy; H | 1967 |
Depression during L-dopa treatment.
Topics: Aged; Amitriptyline; Depression; Dihydroxyphenylalanine; Humans; Male; Middle Aged; Parkinson Diseas | 1969 |
L-dopa in depressed patients.
Topics: Animals; Depression; Dihydroxyphenylalanine; Humans; Parkinson Disease | 1970 |
L-dopa with MK 485 for depression.
Topics: Depression; Dihydroxyphenylalanine; Humans; Hydrazines; Placebos; Propionates | 1970 |
Mental symptoms in Parkinsonian patients treated with L-dopa.
Topics: Aged; Behavior; Depression; Dihydroxyphenylalanine; Dreams; Female; Humans; Imipramine; Male; Memory | 1970 |
L-dopa with MK 485 for depression.
Topics: Depression; Dihydroxyphenylalanine; Humans; Hydrazines; Propionates | 1970 |
L-dopa, parkinsonism, and depression.
Topics: Depression; Dihydroxyphenylalanine; Humans; Parkinson Disease | 1970 |
Subtype of affective psychoses classified by response on amineprecursors and monoamine metabolism.
Topics: 5-Hydroxytryptophan; Amines; Depression; Dihydroxyphenylalanine; Female; Humans; Hydroxyindoleacetic | 1974 |
3 -Methoxy- 4 -hydroxyphenylethylene glycol in human cerebrospinal fluid.
Topics: Chromatography, Gas; Depression; Dihydroxyphenylalanine; Down Syndrome; Ethers; Glycols; Humans; Hyd | 1971 |
Urinary cyclic AMP excretion in depression and mania. Effects of levodopa and lithium carbonate.
Topics: Acute Disease; Adenine Nucleotides; Adult; Affective Symptoms; Bipolar Disorder; Cyclic AMP; Depress | 1971 |
Monamine oxidase inhibitors and brain monamines in clinical conditions.
Topics: Amines; Brain; Brain Chemistry; Depression; Dihydroxyphenylalanine; Dopamine; Humans; Monoamine Oxid | 1971 |
Amine precursors, amines, and false neurotransmitters in depressed patients.
Topics: Biogenic Amines; Biological Transport; Blood Platelets; Carbon Isotopes; Depression; Dihydroxyphenyl | 1972 |
Growth hormone and prolactin in unipolar and bipolar depressed patients: responses to hypoglycemia and L-dopa.
Topics: Age Factors; Aged; Bipolar Disorder; Blood Glucose; Catecholamines; Depression; Dihydroxyphenylalani | 1973 |
Personality (MMPI) and cognitive (WAIS) changes after levodopa treatment.
Topics: Depression; Dihydroxyphenylalanine; Female; Humans; Intelligence; Intelligence Tests; Male; Middle A | 1971 |
Amphetamine psychosis: behavioral and biochemical aspects.
Topics: Adolescent; Adult; Affect; Alcoholism; Amphetamine; Brain; Cognition Disorders; Delusions; Depressio | 1974 |
Catecholamines and depression: a physiological theory of depression.
Topics: Brain; Depression; Dihydroxyphenylalanine; Humans; Methoxyhydroxyphenylglycol; Monoamine Oxidase Inh | 1974 |
[L-5-hydroxytryptophan(L-5-HTP) therapy of Parkinson's disease. 2].
Topics: 5-Hydroxytryptophan; Adult; Aged; Depression; Dihydroxyphenylalanine; Female; Humans; Male; Middle A | 1972 |
[Longtime study on the effects of L-dopa therapy in parkinsonism].
Topics: Aged; Depression; Dihydroxyphenylalanine; Electromyography; Female; Humans; Male; Middle Aged; Parki | 1973 |
Deserpidine antagonism by a tripeptide, L-prolyl-L-leucyglycinamide.
Topics: Animals; Depression; Dihydroxyphenylalanine; Disease Models, Animal; Dose-Response Relationship, Dru | 1973 |
An L-dopa paradox: bipolar behavioral alterations.
Topics: Age Factors; Aged; Arousal; Cognition; Depression; Dihydroxyphenylalanine; Emotions; Humans; Intelli | 1972 |
Growth hormone responses to L-dopa in depressed patients.
Topics: Administration, Oral; Adult; Age Factors; Aged; Depression; Dihydroxyphenylalanine; Growth Hormone; | 1972 |
Psychiatric disturbances in Parkinson's disease.
Topics: Adult; Aged; Barbiturates; Cognition Disorders; Depression; Dihydroxyphenylalanine; Female; Follow-U | 1972 |
Amantadine in Parkinson's disease. Review of more than two years' experience.
Topics: Aged; Amantadine; Ataxia; Constipation; Depression; Diarrhea; Dihydroxyphenylalanine; Drug Synergism | 1972 |
L-dopa for parkinsonism.
Topics: Aged; Amantadine; Depression; Dihydroxyphenylalanine; Female; Follow-Up Studies; Hallucinations; Hum | 1973 |
[Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
Topics: Benzyl Compounds; Carboxy-Lyases; Depression; Dihydroxyphenylalanine; Drug Combinations; Humans; Hyd | 1973 |
[Notes from the Annual Congress 1972 of the German Society of Gerontology].
Topics: Aged; Aging; Arteriosclerosis; Congresses as Topic; Connective Tissue; Depression; Dihydroxyphenylal | 1973 |
Influence of affective states and psychoactive drugs on verbal learning and memory.
Topics: Bipolar Disorder; Carbonates; Depression; Dihydroxyphenylalanine; Humans; Imipramine; Lithium; Memor | 1973 |
[Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
Topics: Aged; Benserazide; Carboxy-Lyases; Depression; Dihydroxyphenylalanine; Drug Evaluation; Drug Therapy | 1973 |
[Combination of L-dopa, desipramine, and a decarboxylase inhibitor in the treatment of depression (author's transl)].
Topics: Adult; Aged; Anxiety; Carbidopa; Carboxy-Lyases; Depression; Desipramine; Dihydroxyphenylalanine; Dr | 1973 |
Failures of L-dopa.
Topics: Aged; Aging; Depression; Dihydroxyphenylalanine; Humans; Male; Medication Errors; Middle Aged; Movem | 1973 |
Letter: Sex differences in growth hormone response.
Topics: Age Factors; Bipolar Disorder; Blood Glucose; Depression; Depression, Chemical; Dihydroxyphenylalani | 1974 |
[Case reports of some mental disorders in parkinsonian patients treated with L-dopa].
Topics: Aged; Anxiety Disorders; Cognition Disorders; Depression; Dihydroxyphenylalanine; Female; Hallucinat | 1974 |
[Differential treatment of Parkinson's disease, with special reference to the possibility of iatrogenic disorders (author's transl)].
Topics: Amantadine; Anesthetics; Anti-Bacterial Agents; Antidepressive Agents; Antihypertensive Agents; Anti | 1974 |
Parkinsonian syndromes. Treatment by association of L-dopa plus decarboxylase inhibitor.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Blood Pressure; Decarboxylation; Depression; Depressio | 1974 |
Relationship of age and mood to monoamine metabolites in cerebrospinal fluid in parkinsonism.
Topics: Age Factors; Aged; Biogenic Amines; Depression; Dihydroxyphenylalanine; Emotions; Female; Homovanill | 1974 |
The treatment of parkinsonism with levodopa.
Topics: Aged; Anorexia Nervosa; Basal Ganglia Diseases; Depression; Dihydroxyphenylalanine; Extrapyramidal T | 1974 |
L-dopa and behavior.
Topics: Animals; Behavior; Depression; Dihydroxyphenylalanine; Haplorhini; Humans; Male; Mice; Sexual Behavi | 1971 |
Suicide on L-dopa.
Topics: Depression; Dihydroxyphenylalanine; Drowning; Female; Humans; Middle Aged; Parkinson Disease; Suicid | 1972 |
A preliminary study of selected emotional changes in Parkinsonians on L-dopa therapy.
Topics: Anxiety; Depression; Dihydroxyphenylalanine; Emotions; Hostility; Humans; Middle Aged; Paranoid Diso | 1972 |
Psychobiological and pharmacological studies of manic-depressive illness.
Topics: Adult; Aged; Bipolar Disorder; Catechols; Depression; Dihydroxyphenylalanine; Dopamine; Female; Glyc | 1972 |
L-dopa treatment of parkinsonism. Clinical observations on the use of amantadine hydrochloride.
Topics: Aged; Amantadine; Chlorides; Depression; Dihydroxyphenylalanine; Drug Hypersensitivity; Female; Foll | 1971 |
Exploration of the anti-depressant potential of L-dopa.
Topics: Animals; Antidepressive Agents; Behavior; Blood Pressure; Carboxy-Lyases; Depression; Dihydroxypheny | 1971 |
[Preliminary psychological findings during treatment of the parkinsonian syndrome with amantadine. Preliminary observations].
Topics: Amantadine; Anxiety; Depression; Dihydroxyphenylalanine; Emotions; Humans; Intelligence Tests; Menta | 1971 |
Psychiatric aspects in Parkinsonism treated with L-dopa.
Topics: Affect; Aged; Antidepressive Agents; Anxiety; Arousal; Barbiturates; Cognition Disorders; Depression | 1971 |
Behavioral effects of l-dopa in man.
Topics: Adult; Aged; Cerebral Cortex; Cognition Disorders; Confusion; Delirium; Delusions; Depression; Dihyd | 1971 |
Adverse reactions during treatment of Parkinson's disease with levodopa.
Topics: Adult; Aged; Coombs Test; Depression; Dihydroxyphenylalanine; Duodenal Ulcer; Female; Gastrointestin | 1971 |
Amines and abnormal mood.
Topics: Affective Symptoms; Blood-Brain Barrier; Catecholamines; Depression; Dihydroxyphenylalanine; Epineph | 1969 |
Psychosis and other psychiatric manifestations of levodopa therapy.
Topics: Adult; Aged; Anxiety; Depression; Dihydroxyphenylalanine; Euphoria; Female; Humans; Male; Middle Age | 1970 |
Present status of psychological reactions to L-DOPA.
Topics: Behavior; Depression; Dihydroxyphenylalanine; Humans; Parkinson Disease; Schizophrenia | 1970 |
Psychic effects in patients treated with levodopa.
Topics: Aged; Depression; Dihydroxyphenylalanine; Female; Humans; Imipramine; Middle Aged; Parkinson Disease | 1970 |
Observations on the effect of amantadine hydrochloride in the treatment of Parkinsonism.
Topics: Aged; Amantadine; Depression; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Muscle Tonu | 1970 |
L-dopa for postencephalitic Parkinsonism.
Topics: Aged; Depression; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Nausea; Parkinson Disea | 1970 |
Mental effects of high-dosage levodopa.
Topics: Adult; Aged; Depression; Dihydroxyphenylalanine; Erectile Dysfunction; Female; Humans; Male; Mental | 1971 |
L-DOPA in the treatment of depressive symptoms.
Topics: Adult; Depression; Dihydroxyphenylalanine; Female; Humans; Male; Mental Disorders; Middle Aged; Remi | 1971 |
[Orientative clinical trials on the effects of dihydroxyphenylalanine (1-dopa) in endogenous depression].
Topics: Adult; Depression; Dihydroxyphenylalanine; Female; Humans | 1965 |